| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.9 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |